DK3513806T3 - Immunogen sammensætning - Google Patents

Immunogen sammensætning Download PDF

Info

Publication number: DK3513806T3
Authority: DK; Denmark
Prior art keywords: immunogenic composition; immunogenic; composition
Prior art date: 2012-12-05

Application number

DK19159001.7T

Other languages

English (en)

Other versions

DK3513806T5 (da

Inventor

Dominique Boutriau

Sophie Marie Jeanne Valentine Germain

Hugues Wallemacq

Original Assignee

Glaxosmithkline Biologicals Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-05

Filing date

2013-12-03

Publication date

2023-02-27

2013-12-03 Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa

2023-02-27 Publication of DK3513806T3 publication Critical patent/DK3513806T3/da

2024-09-02 Application granted granted Critical

2024-09-02 Publication of DK3513806T5 publication Critical patent/DK3513806T5/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

DK19159001.7T 2012-12-05 2013-12-03 Immunogen sammensætning DK3513806T5 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB201221875		2012-12-05
EP13801540.9A EP2928489B1 (en)	2012-12-05	2013-12-03	Immunogenic composition

Publications (2)

Publication Number	Publication Date
DK3513806T3 true DK3513806T3 (da)	2023-02-27
DK3513806T5 DK3513806T5 (da)	2024-09-02

Family

ID=49724573

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK19159001.7T DK3513806T5 (da)	2012-12-05	2013-12-03	Immunogen sammensætning
DK13801540.9T DK2928489T3 (da)	2012-12-05	2013-12-03	Immunogen sammensætning

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK13801540.9T DK2928489T3 (da)	2012-12-05	2013-12-03	Immunogen sammensætning

Country Status (22)

Country	Link
US (2)	US9694064B2 (da)
EP (2)	EP2928489B1 (da)
JP (2)	JP6290918B2 (da)
CN (2)	CN112807422A (da)
AR (1)	AR093712A1 (da)
AU (1)	AU2013354186A1 (da)
BR (1)	BR112015012841B1 (da)
CA (1)	CA2893435A1 (da)
CY (1)	CY1121560T1 (da)
DK (2)	DK3513806T5 (da)
ES (2)	ES2939307T3 (da)
FI (1)	FI3513806T3 (da)
HR (2)	HRP20230359T1 (da)
HU (2)	HUE043091T2 (da)
LT (2)	LT3513806T (da)
PL (2)	PL3513806T3 (da)
PT (2)	PT2928489T (da)
SG (1)	SG11201503861UA (da)
SI (2)	SI2928489T1 (da)
TR (1)	TR201905272T4 (da)
WO (1)	WO2014086787A1 (da)
ZA (1)	ZA201503927B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1896063T1 (sl) *	2005-06-27	2012-03-30	Glaxosmithkline Biolog Sa	Imunogeni sestavek
CN103957931B (zh)	2010-09-03	2017-10-24	瓦尔内瓦奥地利有限责任公司	艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
AR086199A1 (es)	2011-04-22	2013-11-27	Wyeth Llc	Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) *	2012-10-21	2022-03-22	Pfizer Inc	Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
LT3513806T (lt) *	2012-12-05	2023-04-11	Glaxosmithkline Biologicals Sa	Imunogeninė kompozicija
HUE045936T2 (hu) *	2014-06-25	2020-01-28	Glaxosmithkline Biologicals Sa	Clostridium difficile immunogén készítmény
EA035556B1 (ru) *	2014-07-25	2020-07-07	Биосинз С.Р.Л.	Гликоконъюгатные вакцины, содержащие основные структурные единицы молекулярной конструкции, экспрессирующей встроенные множественные эпитопы, для составления вакцины широкого спектра действия против инфекций, вызываемых энтеропатогенными бактериями
ES2870506T3 (es)	2015-02-19	2021-10-27	Immune Biosolutions Inc	Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos
EP3433264A4 (en)	2016-03-21	2019-08-28	Children's Medical Center Corporation	COMPOSITIONS AND METHODS FOR INHIBITING WNT SIGNALING
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
MX2019010948A (es) *	2017-03-15	2020-01-09	Novavax Inc	Métodos y composiciones para inducir respuestas inmunitarias contra clostridium difficile.
CN107397956A (zh) *	2017-08-08	2017-11-28	南开大学	一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用
WO2019143552A1 (en)	2018-01-16	2019-07-25	Children's Medical Center Corporation	Compositions and methods for inhibiting wnt signaling
GB201804092D0 (en) *	2018-03-14	2018-04-25	Imperial Innovations Ltd	Methods and compositions
US10933126B2 (en)	2018-05-03	2021-03-02	The Board Of Regents Of The University Of Oklahoma	Clostridium difficile immunogenic compositions and methods of use
MX2021014097A (es) *	2019-05-21	2022-03-11	Univ California	Composiciones de vacunas para clostridium difficile.
US20230218735A1 (en) *	2020-06-19	2023-07-13	Pfizer Inc.	Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
WO2024127215A2 (en) *	2022-12-13	2024-06-20	Pfizer Inc.	Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
WO2024160901A1 (en)	2023-02-02	2024-08-08	Glaxosmithkline Biologicals Sa	Immunogenic composition

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235877A (en)	1979-06-27	1980-11-25	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
US4866034A (en)	1982-05-26	1989-09-12	Ribi Immunochem Research Inc.	Refined detoxified endotoxin
US4436727A (en)	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
US4935233A (en)	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
US4877611A (en)	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
EP0362278A4 (en)	1987-06-05	1990-05-14	Us Health	Autocrine motility factors in cancer diagnosis and management.
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
ATE115862T1 (de)	1989-02-04	1995-01-15	Akzo Nobel Nv	Tocole als impfstoffadjuvans.
WO1990014837A1 (en)	1989-05-25	1990-12-13	Chiron Corporation	Adjuvant formulation comprising a submicron oil droplet emulsion
DK0761231T3 (da)	1992-06-25	2000-05-08	Smithkline Beecham Biolog	Vaccinepræparat indeholdende adjuvanser
DE69405551T3 (de)	1993-03-23	2005-10-20	Smithkline Beecham Biologicals S.A.	3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
HUT78048A (hu)	1994-10-24	1999-07-28	Ophidian Pharmaceuticals, Inc.	A C. difficile által okozott betegség kezelésére és megelőzésére szolgáló vakcina és antitoxin
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6214341B1 (en)	1997-10-20	2001-04-10	Oravax	Passive immunization against Clostridium difficile disease
US6733760B1 (en) *	1999-04-09	2004-05-11	Techlab, Inc.	Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP2502998A3 (en)	1999-04-09	2013-02-27	Intercell USA, Inc.	Recombinant toxin A/ToxinB vaccine against clostridium difficile
AU2001251013A1 (en)	2000-03-28	2001-10-08	Diadexus, Inc.	Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20090028903A1 (en) *	2005-03-23	2009-01-29	Glaxosmithkline Biologicals, S.A.	Novel use
TWI457133B (zh) *	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
GB0525321D0 (en) *	2005-12-13	2006-01-18	Glaxosmithkline Biolog Sa	Novel compositions
EA015817B1 (ru) *	2006-10-12	2011-12-30	Глаксосмитклайн Байолоджикалс С.А.	Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
GB0711858D0 (en) *	2007-06-19	2007-07-25	Glaxosmithkline Biolog Sa	Vaccine
KR20160005378A (ko)	2007-09-14	2016-01-14	사노피 파스테르 바이오로직스, 엘엘씨	클로스트리듐 디피실리 톡소이드 ａ 및 ｂ를 포함하는 약학적 조성물
ES2553113T3 (es) *	2008-04-16	2015-12-04	Glaxosmithkline Biologicals S.A.	Vacuna
EP2318515A4 (en) *	2008-08-06	2012-11-14	Emergent Product Dev Uk Ltd	DIFFICULT CLOSTRIDIUM VACCINES, AND METHODS OF USE
CN103957931B (zh)	2010-09-03	2017-10-24	瓦尔内瓦奥地利有限责任公司	艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
CN103732750A (zh)	2011-05-27	2014-04-16	葛兰素史密丝克莱恩生物有限公司	免疫原性组合物
LT3513806T (lt) *	2012-12-05	2023-04-11	Glaxosmithkline Biologicals Sa	Imunogeninė kompozicija

2013
- 2013-12-03 LT LTEP19159001.7T patent/LT3513806T/lt unknown
- 2013-12-03 SI SI201331393T patent/SI2928489T1/sl unknown
- 2013-12-03 PL PL19159001.7T patent/PL3513806T3/pl unknown
- 2013-12-03 FI FIEP19159001.7T patent/FI3513806T3/fi active
- 2013-12-03 AU AU2013354186A patent/AU2013354186A1/en not_active Abandoned
- 2013-12-03 DK DK19159001.7T patent/DK3513806T5/da active
- 2013-12-03 HU HUE13801540A patent/HUE043091T2/hu unknown
- 2013-12-03 HR HRP20230359TT patent/HRP20230359T1/hr unknown
- 2013-12-03 WO PCT/EP2013/075405 patent/WO2014086787A1/en active Application Filing
- 2013-12-03 LT LTEP13801540.9T patent/LT2928489T/lt unknown
- 2013-12-03 JP JP2015545783A patent/JP6290918B2/ja active Active
- 2013-12-03 EP EP13801540.9A patent/EP2928489B1/en active Active
- 2013-12-03 CN CN202011473000.5A patent/CN112807422A/zh active Pending
- 2013-12-03 BR BR112015012841-6A patent/BR112015012841B1/pt active IP Right Grant
- 2013-12-03 SG SG11201503861UA patent/SG11201503861UA/en unknown
- 2013-12-03 US US14/649,940 patent/US9694064B2/en active Active
- 2013-12-03 DK DK13801540.9T patent/DK2928489T3/da active
- 2013-12-03 HU HUE19159001A patent/HUE061273T2/hu unknown
- 2013-12-03 PL PL13801540T patent/PL2928489T3/pl unknown
- 2013-12-03 ES ES19159001T patent/ES2939307T3/es active Active
- 2013-12-03 PT PT13801540T patent/PT2928489T/pt unknown
- 2013-12-03 TR TR2019/05272T patent/TR201905272T4/tr unknown
- 2013-12-03 CN CN201380063596.3A patent/CN104884081A/zh active Pending
- 2013-12-03 ES ES13801540T patent/ES2721930T3/es active Active
- 2013-12-03 CA CA2893435A patent/CA2893435A1/en active Pending
- 2013-12-03 PT PT191590017T patent/PT3513806T/pt unknown
- 2013-12-03 AR ARP130104466A patent/AR093712A1/es unknown
- 2013-12-03 EP EP19159001.7A patent/EP3513806B1/en active Active
- 2013-12-03 SI SI201332035T patent/SI3513806T1/sl unknown
2015
- 2015-06-01 ZA ZA2015/03927A patent/ZA201503927B/en unknown
2017
- 2017-05-26 US US15/606,439 patent/US10130694B2/en active Active
2018
- 2018-02-08 JP JP2018020900A patent/JP6626521B2/ja active Active
2019
- 2019-04-16 HR HRP20190711TT patent/HRP20190711T1/hr unknown
- 2019-04-19 CY CY20191100436T patent/CY1121560T1/el unknown

Also Published As

Publication number	Publication date
JP2018104446A (ja)	2018-07-05
ES2721930T3 (es)	2019-08-06
HRP20230359T1 (hr)	2023-06-09
JP2016502551A (ja)	2016-01-28
SI2928489T1 (sl)	2019-05-31
BR112015012841B1 (pt)	2022-05-03
BR112015012841A2 (pt)	2017-09-26
US9694064B2 (en)	2017-07-04
EP2928489B1 (en)	2019-02-27
DK2928489T3 (da)	2019-04-23
PT3513806T (pt)	2023-03-02
AU2013354186A1 (en)	2014-06-12
LT2928489T (lt)	2019-04-10
US10130694B2 (en)	2018-11-20
HRP20190711T1 (hr)	2019-05-31
HUE043091T2 (hu)	2019-08-28
US20150313984A1 (en)	2015-11-05
ES2939307T3 (es)	2023-04-20
CY1121560T1 (el)	2020-05-29
CN104884081A (zh)	2015-09-02
EP2928489A1 (en)	2015-10-14
JP6626521B2 (ja)	2019-12-25
WO2014086787A1 (en)	2014-06-12
CA2893435A1 (en)	2014-06-12
ZA201503927B (en)	2017-11-29
SG11201503861UA (en)	2015-06-29
JP6290918B2 (ja)	2018-03-07
DK3513806T5 (da)	2024-09-02
PT2928489T (pt)	2019-05-28
EP3513806A1 (en)	2019-07-24
HUE061273T2 (hu)	2023-06-28
CN112807422A (zh)	2021-05-18
LT3513806T (lt)	2023-04-11
SI3513806T1 (sl)	2023-04-28
FI3513806T3 (fi)	2023-04-26
US20170340719A1 (en)	2017-11-30
AR093712A1 (es)	2015-06-17
EP3513806B1 (en)	2023-01-25
PL2928489T3 (pl)	2019-07-31
TR201905272T4 (tr)	2019-05-21
PL3513806T3 (pl)	2023-05-15

Publication	Publication Date	Title
DK3513806T3 (da)	2023-02-27	Immunogen sammensætning
HK1231412A1 (zh)	2017-12-22	免疫原性組合物
SI3725778T1 (sl)	2022-02-28	Formulacije enzalutamida
SMT201700110B (it)	2017-03-08	Composizione immunogena
EP3818947C0 (en)	2023-08-30	Fenestrated implant
FR2997014B1 (fr)	2015-03-20	Composition sterile dermo-injectable
BR112014032798A2 (pt)	2017-06-27	composição
SG11201404447WA (en)	2014-08-28	Immunogenic composition
EP2958994A4 (en)	2016-11-23	Vaccine composition
DK2668967T3 (da)	2014-07-07	Implantat
IL238079A0 (en)	2015-05-31	Immunogenic preparation
IL237431A0 (en)	2015-04-30	Immunogenic preparations
EP2876161A4 (en)	2016-03-23	VACCINE
DK2609931T3 (da)	2020-12-07	Immunogen sammensætning
GB201223342D0 (en)	2013-02-06	Immunogenic composition
LT2812013T (lt)	2019-07-10	Kompozicija, skirta džs gydymui
GB201218660D0 (en)	2012-11-28	Immunogenic composition
BR112014032712A2 (pt)	2017-06-27	composição
DK2938356T3 (da)	2020-07-27	Immunogen sammensætning som omfatter mycoplasma-antigener
EP2822599A4 (en)	2015-12-23	VACCINE FORMULATION
EP2837670A4 (en)	2016-01-13	Fluorobiphenyl-containing composition
DK2800573T3 (da)	2021-06-28	Oftalmologisk sammensætning
GB201204968D0 (en)	2012-05-02	Immunogenic composition
GB201204851D0 (en)	2012-05-02	Immunogenic composition